BiotechTube
TopAlliance Biosciences

TopAlliance Biosciences

San Diego, United States· Est.
topalliancebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

TopAlliance Biosciences, founded in 2015 and headquartered in San Diego, is a clinical-stage biopharma developing targeted oncology therapies, most notably antibody-drug conjugates. As the US subsidiary of China's Junshi Biosciences, it benefits from a parent company with a proven track record in antibody development. The company has transitioned to a commercial-stage entity with the US and EU approval of its lead asset, toripalimab (LOQTORZI), for nasopharyngeal carcinoma, and maintains a broader pipeline of novel candidates.

Oncology

Technology Platform

Antibody engineering and development platforms for monoclonal antibodies and antibody-drug conjugates (ADCs), leveraging integrated R&D and manufacturing.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

The global launch of LOQTORZI provides a direct revenue stream and establishes commercial infrastructure.
The growing ADC market offers a significant opportunity for its pipeline of next-generation targeted therapies to address unmet needs in oncology.

Risk Factors

Faces intense competition in the crowded PD-1 inhibitor and ADC markets.
Geopolitical and regulatory complexities arise from its cross-border structure as a Chinese subsidiary operating in the US.
Inherent clinical development risks could impact its pipeline.

Competitive Landscape

Operates in the highly competitive oncology sector, competing with large pharma and biotech companies with approved PD-1 inhibitors (e.g., Merck, Bristol Myers Squibb) and a rapidly expanding field of ADC developers (e.g., AstraZeneca/Daiichi Sankyo, Gilead). Its success depends on differentiation in specific indications and novel ADC technology.

More companies in Biologics / Biosimilars →More companies in United States →